BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-2.66	-2.63	-0.36	0.75	1.09	-0.25
Depreciation & Amortization	0.11	0.11	0.11	0.11	0.1	0.05
Share-Based Compensation	0	0.51	0	0	0	0
Other Operating Activities	1.34	0.71	0.79	-0.85	-0.64	-0.02
Operating Cash Flow	-1.21	-1.3	0.54	0.01	0.55	-0.22
Operating Cash Flow Growth	-	-	5838.52%	-98.34%	-	-
Capital Expenditures	-0.17	-0.15	-0.05	-0	-0.42	-0.01
Acquisitions	0	0.47	0	0	0.35	0
Change in Investments	-0.72	-0.35	-0.51	-0.52	-0.14	-
Other Investing Activities	0.53	-0.36	0.12	0.03	1.53	-
Investing Cash Flow	-0.36	-0.38	-0.45	-0.49	1.32	-0.01
Common Stock Issued	0	5.75	0.15	0	0	0
Other Financing Activities	5.78	0	-0.03	-0.03	-0	-0.18
Financing Cash Flow	5.78	5.75	0.12	-0.03	-0	-0.18
Net Cash Flow	3.86	3.81	-0.01	-0.66	1.93	-0.4
Free Cash Flow	-1.38	-1.45	0.49	0.01	0.13	-0.23
Free Cash Flow Growth	-	-	8065.64%	-95.42%	-	-
Free Cash Flow Margin	-14.15%	-14.85%	4.48%	0.04%	1.15%	-181.24%
Free Cash Flow Per Share	-0.08	-0.09	0.03	0.00	0.02	-0.03

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.